Page last updated: 2024-11-12
n-desmethylrosiglitazone
Description
N-desmethylrosiglitazone: metabolite of rosiglitazone [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 12000328 |
| CHEBI ID | 172565 |
| SCHEMBL ID | 3117517 |
| MeSH ID | M0459400 |
Synonyms (18)
| Synonym |
|---|
| CHEBI:172565 |
| n-desmethylrosiglitazone |
| 257892-31-2 |
| 5-[[4-[2-(pyridin-2-ylamino)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione |
| FT-0666202 |
| Y40U7LI0AG , |
| sb-237216 |
| 2,4-thiazolidinedione, 5-((4-(2-(2-pyridinylamino)ethoxy)phenyl)methyl)- |
| n-desmethyl rosiglitazone |
| 5-[[4-[2-(2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione |
| sb 237216 |
| SCHEMBL3117517 |
| unii-y40u7li0ag |
| DTXSID30475565 |
| AKOS028113778 |
| 2,4-thiazolidinedione, 5-[[4-[2-(2-pyridinylamino)ethoxy]phenyl]methyl]- |
| AS-6148 |
| Q27294240 |
Research Excerpts
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|
| " The pharmacokinetic parameters of RGL and DMRGL were evaluated following oral or intravenous administration of RGL to rats at 10 mg kg-1 with and without pre-treatment (0." | ( Influence of cholestyramine on the pharmacokinetics of rosiglitazone and its metabolite, desmethylrosiglitazone, after oral and intravenous dosing of rosiglitazone: impact on oral bioavailability, absorption, and metabolic disposition in rats.
Mullangi, R; Muzeeb, S; Srinivas, NR; Venkatesh, P, 2006) | 0.33 |
| " The ratio of geometric means (GMR) and 90% confidence intervals (CI) of the coadministration versus monotherapy for Cmax (GMR 95; 90% CI 88, 103) and AUC0-24 h (GMR 103; 90% CI 98, 108) were within the 80-125% bioequivalence criteria." | ( Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics of rosiglitazone.
Cutler, DL; Hanson, ME; Kantesaria, B; Kosoglou, T; Kumar, B; Schiller, JE; Sisk, CM; Statkevich, P, 2015) | 0.42 |
| "Coadministration of vorapaxar with rosiglitazone or drugs metabolized via CYP2C8 is unlikely to cause a significant pharmacokinetic interaction." | ( Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics of rosiglitazone.
Cutler, DL; Hanson, ME; Kantesaria, B; Kosoglou, T; Kumar, B; Schiller, JE; Sisk, CM; Statkevich, P, 2015) | 0.42 |
Bioavailability
Dosage Studied
| Excerpt | Relevance | Reference |
|---|
| " Another objective of the study was to determine the effect of staggered oral CSA dosing at 1, 2 and 4 h after oral RGL administration at 10 mg kg-1." | ( Influence of cholestyramine on the pharmacokinetics of rosiglitazone and its metabolite, desmethylrosiglitazone, after oral and intravenous dosing of rosiglitazone: impact on oral bioavailability, absorption, and metabolic disposition in rats.
Mullangi, R; Muzeeb, S; Srinivas, NR; Venkatesh, P, 2006) | 0.33 |
Drug Classes (1)
| Class | Description |
|---|
| aromatic ether | Any ether in which the oxygen is attached to at least one aryl substituent. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.12
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 12.12 (24.57) | | Research Supply Index | 2.30 (2.92) | | Research Growth Index | 4.42 (4.65) | | Search Engine Demand Index | 0.00 (26.88) | | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 4 (80.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 1 (20.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |